8-K Announcements
6Material company update
May 18, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
May 7, 2026·SEC
Daré Bioscience, Inc.(DARE)Earnings, Financials & Key Ratios
DARE•NASDAQ
Price updated Jun 19, 2026
AboutDaré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.Show more
- Revenue$1M+10429.4%
- EBITDA-$11M+51.3%
- Net Income-$13M-230.6%
- EPS (Diluted)-1.20-150.0%
- Gross Margin-137.55%+99.9%
- EBITDA Margin-1106.68%+99.5%
- Operating Margin-1315.51%+99.5%
- Net Margin-1300.66%+96.9%
- ROE-471.37%
DARE Key Insights
Daré Bioscience, Inc. (DARE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 85.3x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when DARE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DARE Price & Volume
Daré Bioscience, Inc. (DARE) stock price & volume — 10-year historical chart
Loading chart...
DARE Growth Metrics
Daré Bioscience, Inc. (DARE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-53.12%
TTM4366.48%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-617%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-477.44%
Return on Capital
10 Years-855.52%
5 Years-942.15%
3 Years-1464.28%
Last Year-292.04%
DARE Peer Comparison
Daré Bioscience, Inc. (DARE) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TPVG | 202.99M | 5.00 | 4.10 | 36.55% | -19.55% | -3.39% | 1.33 | |
 EVAX | 20.02M | 3.17 | -2.62 | 125.12% | -102.42% | -61.46% | 0.44 | |
 CODA | 112.81M | 10.00 | 27.03 | 30.75% | 17.66% | 8.33% | 0.01 | |
 ANIP | 1.81B | 79.49 | 23.94 | 43.78% | 9.71% | 17.32% | 0.60 | |
 CRVS | 1B | 11.91 | -22.47 | -38.92% | 0.02 | |||
 TXMD | 22.57M | 1.95 | -39.63 | 71.61% | 5.34% | 0.66% | 0.19 | |
 HIMS | 7.79B | 35.47 | 69.55 | 59% | -0.56% | -2.48% | 2.34 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 |
Compare DARE vs Peers
Daré Bioscience, Inc. (DARE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DARE Income Statement
Daré Bioscience, Inc. (DARE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 10M | 2.81M | 9.78K | 1.03M | 1.16M |
Revenue Growth % | -100% | - | - | - | - | - | -71.92% | -99.65% | 10429.36% | 4366.48% |
Cost of Goods Sold | 0 | 625K | 11.14K | 83.33K | 100K | 30.14M | 21.64M | 14.31M | 2.45M | 1.09M |
COGS % of Revenue | - | - | - | - | - | 301.42% | 770.62% | 146210.22% | 237.55% | - |
Gross Profit | 0▲ 0% | -2.44K▲ 0% | -11.14K▼ 356.4% | -83.33K▼ 648.3% | -100K▼ 20.0% | -20.14M▼ 20042.2% | -18.83M▲ 6.5% | -14.3M▲ 24.1% | -1.42M▲ 90.1% | 64.45K▲ 0% |
Gross Margin % | - | - | - | - | - | -201.42% | -670.62% | -146110.22% | -137.55% | 5.57% |
Gross Profit Growth % | -100% | - | -356.43% | -648.25% | -20% | -20042.22% | 6.51% | 24.08% | 90.09% | - |
Operating Expenses | 3.69M | 11.7M | 14.33M | 27.32M | 38.97M | 11.24M | 12.11M | 9.16M | 12.14M | 12.03M |
OpEx % of Revenue | - | - | - | - | - | 112.43% | 431.27% | 93581.98% | 1177.97% | - |
Selling, General & Admin | 2.71M | 5.28M | 5.79M | 6.55M | 8.35M | 11.24M | 11.91M | 9.16M | 8.76M | 8.7M |
SG&A % of Revenue | - | - | - | - | - | 112.43% | 424.15% | 93581.98% | 850.65% | - |
Research & Development | 984.75K | 6.41M | 8.55M | 20.77M | 30.62M | 30.04M | 21.54M | 14.21M | 5.52B | 3.38M |
R&D % of Revenue | - | - | - | - | - | 300.42% | 767.06% | 145188.14% | 536147.3% | - |
Other Operating Expenses | 0 | 143.5K | 0 | 0 | 1 | -30.04M | -21.34M | -14.21M | -5.52B | -46.64K |
Operating Income | -11.18M▲ 0% | -16.88M▼ 51.0% | -14.34M▲ 15.0% | -27.4M▼ 91.0% | -39.07M▼ 42.6% | -31.39M▲ 19.7% | -30.94M▲ 1.4% | -23.45M▲ 24.2% | -13.55M▲ 42.2% | -11.97M▲ 0% |
Operating Margin % | - | - | - | - | - | -313.85% | -1101.89% | -239692.2% | -1315.51% | -1034.38% |
Operating Income Growth % | 69.91% | -51% | 15.03% | -91.02% | -42.57% | 19.67% | 1.42% | 24.2% | 42.21% | - |
EBITDA | -8.45M | -16.88M | -14.33M | -27.36M | -39.04M | -31.36M | -30.9M | -23.41M | -11.4M | -9.94M |
EBITDA Margin % | - | - | - | - | - | -313.61% | -1100.53% | -239259.61% | -1106.68% | -858.88% |
EBITDA Growth % | 77.1% | -99.76% | 15.08% | -90.87% | -42.7% | 19.67% | 1.47% | 24.25% | 51.3% | 54.45% |
D&A (Non-Cash Add-back) | 2.73M | 2.44K | 11.14K | 43.23K | 26.41K | 24.2K | 38.36K | 42.33K | 2.15M | 2.03M |
EBIT | -11.18M | -11.7M | -14.26M | -27.4M | -39.07M | -31.39M | -30.74M | -23.45M | -13.55M | -11.97M |
Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -142.97K | -206.39K |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 679.74K | 261.54K |
Interest Expense | 322.63K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 822.71K | 467.93K |
Other Income/Expense | -323K | 143.5M | 81.05K | 1.51K | 372.41K | 437.75K | 778.49K | 19.4M | 153.06K | -50.74K |
Pretax Income | -11.5M▲ 0% | -16.74M▼ 45.5% | -14.26M▲ 14.8% | -27.4M▼ 92.1% | -38.7M▼ 41.2% | -30.95M▲ 20.0% | -30.16M▲ 2.5% | -4.05M▲ 86.6% | -13.4M▼ 230.6% | -12.02M▲ 0% |
Pretax Margin % | - | - | - | - | - | -309.48% | -1074.17% | -41430.9% | -1300.66% | -1038.77% |
Income Tax | 0 | 10.23M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | -61.13% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -11.5M▲ 0% | -16.74M▼ 45.5% | -14.26M▲ 14.8% | -27.4M▼ 92.1% | -38.7M▼ 41.2% | -30.95M▲ 20.0% | -30.16M▲ 2.5% | -4.05M▲ 86.6% | -13.4M▼ 230.6% | -12.02M▲ 0% |
Net Margin % | - | - | - | - | - | -309.48% | -1074.17% | -41430.9% | -1300.66% | -1038.77% |
Net Income Growth % | 70.73% | -45.52% | 14.79% | -92.1% | -41.22% | 20.02% | 2.54% | 86.56% | -230.55% | -617% |
Net Income (Continuing) | -11.5M | -16.74M | -14.26M | -27.4M | -38.7M | -30.95M | -30.16M | -4.05M | -13.4M | -12.02M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -3.56▲ 0% | -30.16▼ 747.2% | -10.99▲ 63.6% | -10.93▲ 0.5% | -7.52▲ 31.2% | -4.39▲ 41.6% | -4.15▲ 5.5% | -0.48▲ 88.4% | -1.20▼ 150.0% | -0.83▲ 0% |
EPS Growth % | 88.14% | -747.19% | 63.56% | 0.55% | 31.2% | 41.62% | 5.47% | 88.43% | -150% | -477.44% |
EPS (Basic) | -3.56 | -30.16 | -10.99 | -10.93 | -7.52 | -4.39 | -4.15 | -0.48 | -1.20 | - |
Diluted Shares Outstanding | 269.36K | 894.37K | 1.3M | 2.51M | 5.1M | 7.05M | 7.28M | 8.5M | 111.79M | 14.52M |
Basic Shares Outstanding | 269.36K | 894.37K | 1.3M | 2.51M | 5.1M | 7.05M | 7.28M | 8.5M | 111.79M | 14.52M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
DARE Balance Sheet
Daré Bioscience, Inc. (DARE) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 8.35M | 7.24M | 6.44M | 6.98M | 55.3M | 43.04M | 17.54M | 18.45M | 27.06M | 21.66M |
Cash & Short-Term Investments | 7.56M | 6.81M | 4.78M | 4.67M | 51.67M | 34.67M | 10.48M | 15.7M | 24.71M | 18.52M |
Cash Only | 7.56M | 6.81M | 4.78M | 4.67M | 51.67M | 34.67M | 10.48M | 15.7M | 24.71M | 18.52M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 284.21K | 31.04K | 555.21K | 460.17K | 1.15M | 1.7M | 949.21K | 229.98K | 573.06K | 287.76K |
Days Sales Outstanding | - | - | - | - | - | 62.17 | 123.39 | 8.58K | 203.04 | 111.82 |
Inventory | 311.57K | -402.69M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 193.5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 387.09K | 680.75K |
Total Non-Current Assets | 5.91M | 587.36K | 998.86K | 566.8K | 511.16K | 787.63K | 3.74M | 3.65M | 5.41M | 6.17M |
Property, Plant & Equipment | 0 | 9.4K | 551.81K | 277.48K | 242.71K | 522.83K | 1.98M | 2.54M | 4.4M | 3.73M |
Fixed Asset Turnover | - | - | - | - | - | 19.13x | 1.42x | 0.00x | 0.23x | 0.25x |
Goodwill | 5.19M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 335K | 0 | 0 | 300K |
Other Non-Current Assets | 723.19K | 577.97K | 447.05K | 289.32K | 268.45K | 264.8K | 1.43M | 1.11M | 1.01M | 2.14M |
Total Assets | 14.26M▲ 0% | 7.83M▼ 45.1% | 7.44M▼ 4.9% | 7.55M▲ 1.5% | 55.81M▲ 639.1% | 43.83M▼ 21.5% | 21.28M▼ 51.4% | 22.1M▲ 3.8% | 32.47M▲ 46.9% | 27.83M▲ 0% |
Asset Turnover | - | - | - | - | - | 0.23x | 0.13x | 0.00x | 0.03x | 0.04x |
Asset Growth % | -62.16% | -45.11% | -4.91% | 1.45% | 639.1% | -21.47% | -51.44% | 3.85% | 46.94% | 121.65% |
Total Current Liabilities | 966.65K | 1.09M | 5.61M | 7.66M | 16.05M | 31.62M | 20.48M | 21.61M | 23.69M | 21.12M |
Accounts Payable | 308.22K | 459.7K | 1.08M | 1.02M | 2.1M | 2.03M | 3.39M | 1.46M | 1.2M | 1.23M |
Days Payables Outstanding | - | 268.47 | 35.5K | 4.47K | 7.68K | 24.56 | 57.11 | 37.15 | 179.08 | 504.3 |
Short-Term Debt | 0 | 0 | 0 | 367.29K | 0 | 0 | 0 | 0 | 0 | 1.21M |
Deferred Revenue (Current) | 0 | 0 | 2.02M | 1.56M | 10.54M | 18.3M | 13.74M | 16.56M | 19.65M | 64.69M |
Other Current Liabilities | 0 | 0 | 715.2K | 2.16M | 1.53M | 1.72M | 2.08M | 805.61K | 21.97K | 529.33K |
Current Ratio | 8.64x | 6.64x | 1.15x | 0.91x | 3.44x | 1.36x | 0.86x | 0.85x | 1.14x | 1.03x |
Quick Ratio | 8.31x | 375.72x | 1.15x | 0.91x | 3.44x | 1.36x | 0.86x | 0.85x | 1.14x | 1.03x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -392.48 |
Total Non-Current Liabilities | 392 | 9.71K | 1.39M | 1.04M | 1M | 1.09M | 5.85M | 6.5M | 5.95M | 5.97M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.56M |
Capital Lease Obligations | 0 | 0 | 389.56K | 41.84K | 0 | 90.35K | 935.74K | 754.38K | 559.37K | 2.04M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 392 | 0 | 1M | 0 | 0 | 0 | 3.91M | 4.75M | 5.39M | 0 |
Total Liabilities | 967.04K | 1.1M | 7M | 8.7M | 17.05M | 32.71M | 26.33M | 28.11M | 29.63M | 27.09M |
Total Debt | 0 | 0 | 800.45K | 756.84K | 270.55K | 488.74K | 1.4M | 1.3M | 2.66M | 7.18M |
Net Debt | -7.56M | -6.81M | -3.98M | -3.91M | -51.4M | -34.18M | -9.07M | -14.4M | -22.06M | -11.34M |
Debt / Equity | - | - | 1.82x | - | 0.01x | 0.04x | - | - | 0.93x | 9.78x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.72x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.14x |
Interest Coverage | -34.65x | - | - | - | - | - | - | - | -16.47x | -25.58x |
Total Equity | 13.29M▲ 0% | 6.73M▼ 49.4% | 440.83K▼ 93.4% | -1.15M▼ 361.3% | 38.75M▲ 3464.9% | 11.11M▼ 71.3% | -5.05M▼ 145.4% | -6.01M▼ 19.1% | 2.84M▲ 147.3% | 734.45K▲ 0% |
Equity Growth % | 1.39% | -49.4% | -93.45% | -361.27% | 3464.87% | -71.33% | -145.42% | -19.11% | 147.28% | -29.15% |
Book Value per Share | 49.35 | 7.52 | 0.34 | -0.46 | 7.60 | 1.58 | -0.69 | -0.71 | 0.03 | 0.05 |
Total Shareholders' Equity | 13.29M | 6.73M | 440.83K | -1.15M | 38.75M | 11.11M | -5.05M | -6.01M | 2.84M | 734.45K |
Common Stock | 605 | 1.14K | 1.97K | 4.16K | 8.39K | 8.48K | 10K | 870 | 1.45K | 1.46K |
Retained Earnings | -12.23M | -28.97M | -44.02M | -71.43M | -110.13M | -141.07M | -171.24M | -175.29M | -188.69M | -191.69M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -18.08K | -96.73K | -102.63K | -91.39K | -154.97K | -351.31K | -360.9K | -428.81K | -421.62K | -377.08K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DARE Cash Flow Statement
Daré Bioscience, Inc. (DARE) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -2.54M | -10.27M | -13.32M | -25.23M | -28.76M | -18.09M | -38.86M | 5.39M | -9.89B | -9.94M |
Operating CF Margin % | - | - | - | - | - | -180.88% | -1383.84% | 55133.35% | -959613.39% | - |
Operating CF Growth % | 92.43% | -304.25% | -29.67% | -89.52% | -13.98% | 37.11% | -114.81% | 113.88% | -183366.91% | -122.73% |
Net Income | -11.5M | -16.74M | -14.26M | -27.4M | -38.7M | -30.95M | -30.16M | -4.05M | -13.4B | -12.02M |
Depreciation & Amortization | 0 | 2.44K | 11.14K | 43.23K | 26.41K | 24.2K | 38.36K | 42.33K | 1.63B | 2.3M |
Stock-Based Compensation | 15.83K | 139.35K | 462.24K | 742.03K | 1.6M | 2.16M | 2.53M | 2.2M | 1.5B | 814.08K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 7.81M | 5.69M | -231.22K | -162.17K | -421.73K | -23.06K | -837.42K | 1.39M | 382.57M | 1.1M |
Working Capital Changes | 1.14M | 634.08K | 706.19K | 1.54M | 8.73M | 10.7M | -10.43M | 5.81M | -210.74K | -2.13M |
Change in Receivables | 662.06K | 253.17K | -201.42K | 95.04K | -685.15K | -557.84K | 753.95K | 719.23K | -343.08K | -582.52K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 753.1K | 151.49K | 608.65K | -61.85K | 1.08M | -75.13K | 1.36M | -1.93M | -255.15K | -268.39K |
Cash from Investing | 9.92M | -518.84K | 6.14M | -17.63K | -14.52K | -63.07K | -629.43K | -573.05K | -385.28M | -227.95K |
Capital Expenditures | 0 | -11.84K | 0 | -17.63K | -14.52K | -63.07K | -629.43K | -573.05K | -385.28M | -227.95K |
CapEx % of Revenue | - | - | - | - | - | 0.63% | 22.42% | 5856.97% | 37398.62% | 19.7% |
Acquisitions | 9.92M | -507K | 6.14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 9.92M | -507K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 155K | 10.11M | 5.15M | 25.13M | 75.85M | 1.34M | 15.64M | 433.83K | 19.28B | 18.32M |
Debt Issued (Net) | 155K | 0 | 0 | 367.29K | 0 | 0 | 267.19K | -17.56K | -388.79K | -1.28M |
Equity Issued (Net) | 0 | 10.11M | 5.15M | 24.76M | 75.31M | 1.22M | 9.35M | 453.58K | 20.93M | 20.89M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 2 | 0 | 0 | 532.67K | 124.6K | 6.02M | -2.19K | 19.26B | -1.29M |
Net Change in Cash | 7.52M▲ 0% | -753.96K▼ 110.0% | -2.03M▼ 168.7% | -110.64K▲ 94.5% | 47M▲ 42584.3% | -17M▼ 136.2% | -23.86M▼ 40.3% | 5.19M▲ 121.7% | 9.01B▲ 173660.9% | 8.19M▲ 0% |
Free Cash Flow | -2.54M▲ 0% | -10.28M▼ 304.7% | -13.32M▼ 29.5% | -25.25M▼ 89.6% | -28.78M▼ 14.0% | -18.15M▲ 36.9% | -39.49M▼ 117.5% | 4.82M▲ 112.2% | -10.27B▼ 213141.3% | -10.16M▲ 0% |
FCF Margin % | - | - | - | - | - | -181.52% | -1406.26% | 49276.38% | -997012.02% | -878.3% |
FCF Growth % | 92.54% | -304.71% | -29.52% | -89.65% | -13.96% | 36.93% | -117.54% | 112.21% | -213141.27% | -269.02% |
FCF per Share | -9.43 | -11.49 | -10.26 | -10.07 | -5.65 | -2.58 | -5.43 | 0.57 | -91.88 | -0.70 |
FCF Conversion (FCF/Net Income) | 0.22x | 0.61x | 0.93x | 0.92x | 0.74x | 0.58x | 1.29x | -1.33x | 737.79x | 0.85x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 837 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DARE Key Ratios
Daré Bioscience, Inc. (DARE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -87.13% | -167.23% | -398.02% | - | -205.82% | -124.12% | -994.69% | - | -471.37% | 763.44% |
Return on Invested Capital (ROIC) | - | -447.9% | - | - | - | - | - | - | - | 58.07% |
Gross Margin | - | - | - | - | - | -201.42% | -670.62% | -146110.22% | -137.55% | 5.57% |
Net Margin | - | - | - | - | - | -309.48% | -1074.17% | -41430.9% | -1300.66% | -1038.77% |
Debt / Equity | - | - | 1.82x | - | 0.01x | 0.04x | - | - | 0.93x | 9.78x |
Interest Coverage | -34.65x | - | - | - | - | - | - | - | -16.47x | -25.58x |
FCF Conversion | 0.22x | 0.61x | 0.93x | 0.92x | 0.74x | 0.58x | 1.29x | -1.33x | 737.79x | 0.85x |
Revenue Growth | -100% | - | - | - | - | - | -71.92% | -99.65% | 10429.36% | 4366.48% |
Related:DARE Dividend History·DARE Revenue History·DARE Price History·DARE P/E History·DARE Financial Ratios·DARE Institutional Holders
DARE SEC Filings & Documents
Daré Bioscience, Inc. (DARE) SEC filings — annual & quarterly reports (10-K, 10-Q)
DARE Frequently Asked Questions
Daré Bioscience, Inc. (DARE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Daré Bioscience, Inc. (DARE) reported $1.2M in revenue for fiscal year 2025. This represents a 279% increase from $0.3M in 2011.
Daré Bioscience, Inc. (DARE) grew revenue by 10429.4% over the past year. This is strong growth.
Daré Bioscience, Inc. (DARE) reported a net loss of $12.0M for fiscal year 2025.
Dividend & Returns
Daré Bioscience, Inc. (DARE) has a return on equity (ROE) of -471.4%. Negative ROE indicates the company is unprofitable.
Daré Bioscience, Inc. (DARE) had negative free cash flow of $10.2M in fiscal year 2025, likely due to heavy capital investments.